HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Nathaniel R. Evans, III Cameron D. Wright Mark S. Allen Henning A. Gaissert Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Evans, N. R. Articles by Gaissert, H. A. Search for Related Content PubMed Articles by Evans, N. R., III Articles by Gaissert, H. A. Related Collections Lung - cancer

J Thorac Cardiovasc Surg 2010;139:991-996
© 2010 The American Association for Thoracic Surgery

General Thoracic Surgery

The impact of induction therapy on morbidity and operative mortality after resection of primary lung cancer

^a Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Mass
^b Duke Clinical Research Institute, Duke University, Durham, NC
^c Division of Thoracic Surgery, Mayo Clinic, Rochester, Minn

Presented at the Annual Meeting of the Western Thoracic Surgical Association, Banff, AB, Canada, June 24–27, 2009.

Received for publication June 26, 2009; revisions received October 15, 2009; accepted for publication November 4, 2009.

^_* Address for reprints: Henning A. Gaissert, MD, Massachusetts General Hospital, Blake 1570, Fruit Street, Boston, MA 02114. (Email: hgaissert{at}partners.org).

Objective: Use and operative results of neoadjuvant therapy before major elective resection for primary lung cancer were examined in the Society of Thoracic Surgeons General Thoracic Surgical Database.

Methods: Lobectomy and pneumonectomy for primary lung cancer were identified in 12,201 patients between January 2002 and June 2008. After excluding procedures for missing clinical staging or end points; institutions with more than 10% missing data for clinical stage, discharge mortality, or length of stay; and patients treated with chemotherapy or radiation for unrelated disease, there remained 5376 resections. Study end points were discharge mortality, length of stay more than 14 days, and major morbidity. Multivariate analysis using propensity scores stratified into quintiles measured the effect of induction therapy.

Results: In 525 of 5376 procedures (9.8%), chemotherapy (n = 153), radiotherapy (23), or chemoradiotherapy (349) preceded resection. Compared with resection only, patients receiving induction therapy were younger and had fewer comorbidities, more reoperative surgery, and higher rates of pneumonectomy. Clinical IIIA-N2 disease was treated with induction therapy in only 203 of 397 patients (51.1%). Propensity-adjusted rates detected no difference in discharge mortality, prolonged length of stay, or a composite of major morbidity for patients receiving induction therapy. Similar results were obtained in a logistic regression model (discharge mortality P = .9883; prolonged hospital stay P = .9710; major morbidity P = .9678).

Conclusion: Less than 10% of all major lung resections for primary carcinoma and just more than half of all resections for clinical stage IIIA-N2 disease are preceded by neoadjuvant chemotherapy or radiation. This study does not support concerns over excessive operative risk of induction therapy.

This article has been cited by other articles:

				A. W. Kim, D. J. Boffa, Z. Wang, and F. C. Detterbeck An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer J. Thorac. Cardiovasc. Surg., January 1, 2012; 143(1): 55 - 63. [Abstract] [Full Text] [PDF]